Sinopharm Group released its 2026 interim report, with net profit attributable to the parent company at 880 million yuan, down 7.25% from the same period last year. Total operating revenue was 26.728 billion yuan, up 4.27% year-on-year, marking four consecutive years of growth. Net cash flow from operating activities was negative 2.634 billion yuan, a decrease of 1.124 billion yuan from the same period last year. The company's latest asset-liability ratio was 42.93%, gross margin was 5.98%, return on equity was 4.68%, and diluted earnings per share was 1.17 yuan.
China National Medicines Corp LtdNet profit down 7.25% year-on-year, with negative operating cash flow.
